Sign in
CompletedPhase 2

REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant

Key facts

Who runs it
Duke University
Where
Durham, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
142 people enrolled
Started
28 Jun 2023
Ended
7 Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Suvorexant 20 mg
  • Placebo
Record updated
15 January 2026

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age 65 and older
  • Undergoing non-cardiac, non-intracranial surgery, any surgical procedure not involving the skull, brain, cerebrovascular structures
  • Scheduled postoperative inpatient overnight stay
  • Able to give informed consent or has legally authorized representative able to give informed consent on their behalf
  • English-speaking

Who cannot take part

  • Use of outpatient sedating sleep aids > 2 times per any week in 1 month preceding day of surgery. Sedating sleep aids, *See list Below
  • Use of systemic (oral, intravenous, intramuscular, subcutaneous) moderate or strong CYP3A inhibitors within 1 week prior to surgery, *See list below
  • Use of systemic (oral, intravenous, intramuscular, subcutaneous) moderate or strong CYP3A inducers within 1 week prior to surgery, *See list below
  • Undergoing surgery that will result in inability to take medications by mouth including laryngectomy, tracheostomy, and oral resection/reconstructive surgery
  • Undergoing surgery that will require postoperative strict bowel rest, including gastrectomy, esophagectomy, and pancreaticoduodenectomy
  • Undergoing surgery in an area that will make it unsafe to wear a headband, such as scalp or forehead procedures
  • Inappropriate for study inclusion based on the judgement of the principal investigator; Exclusionary Medications:; Moderate CYP3A inhibitors: Amprenavir, Aprepitant, Atazanavir, Ciprofloxacin, Diltiazem, Erythromycin, Fluconazole, Fosamprenavir, Imatinib, Verapamil, grapefruit juice; Strong CYP3A inhibitors: Ketoconazole, Itraconazole, Posaconazole, Clarithromycin, Nefazodone, Ritonavir, Saquinavir, Nelfinavir, Indinavir, Boceprevir, Telaprevir, Telithromycin, Conivaptan; Moderate/Strong CYP3A inducers: Apalutamide, Carbamazepine, Enzalutamide, Ivosidenib, lumacaftor, Mitotane, Phenytoin, Rifampin, St. John's wort, Bosentan, Cenobamate, Dabrafenib, Efavirenz, Etravirine, Lorlatinib, Pexidartinib, Phenobarbital, Primidone, Sotorasib; Sedating sleep aids: Mirtazapine, Trazodone, Flurazepam, Temazepam, Triazolam, Estazolam, Quazepam, Clonazepam, Lorazepam, Midazolam, Alprazolam, Diazepam, Zolpidem, Zaleplon, Eszopiclone, Diphenhydramine, Doxylamine, Hydroxyzine, Suvorexant, Doxepin
  • History of psychotic disorder, including schizophrenia, schizoaffective disorder, schizophreniform or brief psychotic disorder
  • History of severe sleep apnea or obesity hypoventilation syndrome requiring home bilevel positive airway pressure therapy or home ventilator or other forms of noninvasive ventilation
  • Chronic lung disease requiring home oxygen therapy
  • History of narcolepsy
  • History of liver failure with documented international normalized ratio (INR) of >1.2 or with history of hepatic encephalopathy
  • Inmate of correctional facility
  • Body mass index> 40
  • Legal blindness
  • Unable to perform study related questionnaires and assessments
  • Current or planned administration of digoxin, or is currently experiencing digoxin toxicity

Where in United States

  • Duke University Medical CenterDurham, United States

About the trial

What the trial wants to find out

This research study will evaluate the effectiveness of postoperative administration of a drug called suvorexant, to improve postoperative sleep and decrease the severity of delirium (serious confusion) in adults 65 years and older undergoing non-cardiac surgery.

The 2 groups in the trial

  • Suvorexant ArmExisting treatment, for comparison

    Treatment: Suvorexant 20 mg

  • Placebo ArmPlacebo, for comparison

    Treatment: Placebo

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Suvorexant to Improve Postoperative Sleep and Reduce Delirium Severity in Older Surgical Patients: A Double-blinded, Randomized, Placebo-controlled Trial
Publications
Record updated
15 January 2026